Recent studies in animal models have highlighted the crucial role of neuronal activity in OPC proliferation and de novo myelination (for a review, see Sampaio-Baptista and Johansen-Berg, 2017)
In simple terms, a substance generally must meet one of these requirements: It has an official USP or National Formulary monograph It is already part of an FDA-approved drug product It appears on the FDAs official 503A Bulks List The important point is this: BPC-157, TB-500, and injectable GHK-Cu are not FDA-approved drugs, and they are not currently on the formal 503A Bulks List
It is studied in preclinical models to investigate tissue remodeling and repair, extracellular matrix regulation, antioxidant and anti-inflammatory effects, and cellular senescence modulation
It worked: the patients pain was relieved
It can make the skin feel greasy, heavy, or uncomfortable
Its effects are subject to a negative feedback mechanism by somatostatin, and thus it cant push HGH levels above physiological norms